BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37890725)

  • 1. Reply to: " 'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison - some issues".
    Sheehan Y; Grebely J; Lloyd AR
    J Hepatol; 2024 Mar; 80(3):e107-e108. PubMed ID: 37890725
    [No Abstract]   [Full Text] [Related]  

  • 2. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'One-stop-shop' point-of-care hepatitis C RNA testing intervention in the prison - some issues.
    Dai CY; Batsaikhan B; Huang CF
    J Hepatol; 2024 Mar; 80(3):e106-e107. PubMed ID: 37562747
    [No Abstract]   [Full Text] [Related]  

  • 4. Consensus recommendations on the management of hepatitis C in Australia's prisons.
    Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
    Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework.
    Lafferty L; Sheehan Y; Cochrane A; Grebely J; Lloyd AR; Treloar C
    Addiction; 2023 Jun; 118(6):1153-1160. PubMed ID: 36683132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar.
    Draper BL; Htay H; Pedrana A; Yee WL; Howell J; Pyone Kyi K; Naing W; Sanda Aung K; Markby J; Easterbrook P; Bowring A; Aung W; Sein YY; Nwe N; Myint KT; Shilton S; Hellard M
    Liver Int; 2021 Nov; 41(11):2578-2589. PubMed ID: 34153155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.
    Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P
    Hepatology; 2021 Nov; 74(5):2366-2379. PubMed ID: 34105797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
    Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
    Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
    J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
    Johnson A; Shearer J; Thompson C; Jelley R; Aldridge J; Allsop C; Kerry J; Jones D; McCullough F; Miller C; Valappil M; Taha Y; Masson S; Jefferson T; Lawton C; Christensen L; McPherson S
    J Viral Hepat; 2023 Dec; 30(12):914-921. PubMed ID: 37700492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "That was quick, simple, and easy": Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison.
    Lafferty L; Cochrane A; Sheehan Y; Treloar C; Grebely J; Lloyd AR
    Int J Drug Policy; 2022 Jan; 99():103456. PubMed ID: 34560624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prisons, prisoners, and hepatitis C.
    Ferguson L; Batey R
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1184-6. PubMed ID: 20594243
    [No Abstract]   [Full Text] [Related]  

  • 14. Mixed-methods evaluation of point-of-care hepatitis C virus RNA testing in a Scottish prison.
    Byrne CJ; Malaguti A; Inglis SK; Dillon JF
    BMJ Open; 2023 Apr; 13(4):e068604. PubMed ID: 37037621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study.
    Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J;
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.
    Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C;
    Int J Drug Policy; 2020 Mar; 77():102693. PubMed ID: 32045828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
    Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
    J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs.
    Snow KJ; Young JT; Preen DB; Lennox NG; Kinner SA
    BMC Public Health; 2014 Aug; 14():830. PubMed ID: 25113132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.